Genmab A/S (NASDAQ:GMAB) Shares Acquired by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC increased its position in shares of Genmab A/S (NASDAQ:GMAB) by 295.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,257 shares of the company’s stock after acquiring an additional 939 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Genmab A/S were worth $26,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Sequoia Financial Advisors LLC boosted its position in shares of Genmab A/S by 27.8% during the 4th quarter. Sequoia Financial Advisors LLC now owns 22,204 shares of the company’s stock worth $463,000 after acquiring an additional 4,835 shares in the last quarter. Callan Family Office LLC acquired a new position in Genmab A/S in the fourth quarter valued at approximately $225,000. Lindbrook Capital LLC increased its stake in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Genmab A/S during the fourth quarter worth approximately $2,463,000. Finally, Aigen Investment Management LP purchased a new stake in shares of Genmab A/S during the 4th quarter worth approximately $257,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, Truist Financial decreased their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $19.84 on Friday. The stock has a fifty day moving average price of $21.09 and a 200 day moving average price of $22.25. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.02. The company has a market cap of $13.13 billion, a PE ratio of 11.40, a P/E/G ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.